Four-month Moxifloxacin-based regimens for drug-sensitive tuberculosis

New England Journal of Medicine

Volumn 371, Issue 17, 2014, Pages 1577-1587

  Gillespie, Stephen H ^a   Crook, Angela M ^b   McHugh, Timothy D ^b   Mendel, Carl M ^c   Meredith, Sarah K ^b   Murray, Stephen R ^c   Pappas, Frances ^c   Phillips, Patrick P J ^b   Nunn, Andrew J ^b  

^a UNIVERSITY OF ST ANDREWS   (United Kingdom)

^b UNIVERSITY COLLEGE LONDON   (United Kingdom)

^c TB Alliance   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ETHAMBUTOL; ISONIAZID; MOXIFLOXACIN; PLACEBO; PYRAZINAMIDE; RIFAMPICIN; QUINOLONE DERIVATIVE; TUBERCULOSTATIC AGENT;

ADULT; ARTICLE; CARDIOTOXICITY; CONTROLLED STUDY; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; DRUG FATALITY; DRUG SAFETY; DRUG SUBSTITUTION; DRUG TREATMENT FAILURE; DRUG WITHDRAWAL; FEMALE; FOLLOW UP; HUMAN; HYPERGLYCEMIA; HYPOGLYCEMIA; LUNG TUBERCULOSIS; MAJOR CLINICAL STUDY; MALE; PERIPHERAL NEUROPATHY; PHASE 3 CLINICAL TRIAL; RANDOMIZED CONTROLLED TRIAL; RELAPSE; SEIZURE; SENSITIVITY ANALYSIS; TENDINITIS; COMPARATIVE STUDY; CONTROLLED CLINICAL TRIAL; DRUG ADMINISTRATION; DRUG COMBINATION; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; ISOLATION AND PURIFICATION; KAPLAN MEIER METHOD; MULTICENTER STUDY; MYCOBACTERIUM TUBERCULOSIS; YOUNG ADULT;

ADULT; ANTITUBERCULAR AGENTS; DOUBLE-BLIND METHOD; DRUG ADMINISTRATION SCHEDULE; DRUG THERAPY, COMBINATION; ETHAMBUTOL; FEMALE; FLUOROQUINOLONES; HIV SEROPOSITIVITY; HUMANS; ISONIAZID; KAPLAN-MEIER ESTIMATE; MALE; MYCOBACTERIUM TUBERCULOSIS; PYRAZINAMIDE; RIFAMPIN; TUBERCULOSIS, PULMONARY; YOUNG ADULT;

EID: 84908126151     PISSN: 00284793     EISSN: 15334406     Source Type: Journal    
DOI: 10.1056/NEJMoa1407426     Document Type: Article

References (30)

1. Gillespie SH, Billington O. Activity of moxifloxacin against mycobacteria. J Antimicrob Chemother 1999;44:393-5.
2. Falzon D, Jaramillo E, Schünemann HJ, et al. WHO guidelines for the programmatic management of drug-resistant tuberculosis: 2011 update. Eur Respir J 2011; 38:516-28.
3. Johnston JC, Shahidi NC, Sadatsafavi M, Fitzgerald JM. Treatment outcomes of multidrug-resistant tuberculosis: a systematic review and meta-analysis. PLoS One 2009;4(9):e6914.
4. Ginsberg AM. Tuberculosis drug development: progress, challenges, and the road ahead. Tuberculosis (Edinb) 2010;90: 162-7.
5. Grossman RF, Hsueh P-R, Gillespie SH, Blasi F. Community-acquired pneumonia and tuberculosis: differential diagnosis and the use of fluoroquinolones. Int J Infect Dis 2014;18:14-21.
6. Müller M, Stass H, Brunner M, Muller JG, Lackner E, Eichler HG. Penetration of moxifloxacin into peripheral compartments in humans. Antimicrob Agents Chemother 1999;43:2345-9.
7. Lubasch A, Keller I, Borner K, Koeppe P, Lode H. Comparative pharmacokinetics of ciprofloxacin, gatifloxacin, grepafloxacin, levofloxacin, trovafloxacin, and moxifloxacin after single oral administration in healthy volunteers. Antimicrob Agents Chemother 2000;44:2600-3.
8. Sullivan JT, Woodruff M, Lettieri J, et al. Pharmacokinetics of a once-daily oral dose of moxifloxacin (Bay 12-8039), a new enantiomerically pure 8-methoxy quinolone. Antimicrob Agents Chemother 1999; 43:2793-7.
9. Miyazaki E, Miyazaki M, Chen JM, Chaisson RE, Bishai WR. Moxifloxacin (BAY12-8039), a new 8-methoxyquinolone, is active in a mouse model of tuberculosis. Antimicrob Agents Chemother 1999;43: 85-9.
10. Gosling RD, Uiso LO, Sam NE, et al. The bactericidal activity of moxifloxacin in patients with pulmonary tuberculosis. Am J Respir Crit Care Med 2003;168:1342-5.
11. Pletz MWR, De Roux A, Roth A, Neumann K-H, Mauch H, Lode H. Early bactericidal activity of moxifloxacin in treatment of pulmonary tuberculosis: a prospective, randomized study. Antimicrob Agents Chemother 2004;48:780-2.
12. Nuermberger EL, Yoshimatsu T, Tyagi S, et al. Moxifloxacin-containing regimen greatly reduces time to culture conversion in murine tuberculosis. Am J Respir Crit Care Med 2004;169:421-6.
13. Nuermberger EL, Yoshimatsu T, Tyagi S, et al. Moxifloxacin-containing regimens of reduced duration produce a stable cure in murine tuberculosis. Am J Respir Crit Care Med 2004;170:1131-4.
14. Rustomjee R, Lienhardt C, Kanyok T, et al. A phase II study of the sterilising activities of ofloxacin, gatifloxacin and moxifloxacin in pulmonary tuberculosis. Int J Tuberc Lung Dis 2008;12:128-38.
15. Conde MB, Efron A, Loredo C, et al. Moxifloxacin versus ethambutol in the initial treatment of tuberculosis: a doubleblind, randomised, controlled phase II trial. Lancet 2009;373:1183-9.
16. Dorman SE, Johnson JL, Goldberg S, et al. Substitution of moxifloxacin for isoniazid during intensive phase treatment of pulmonary tuberculosis. Am J Respir Crit Care Med 2009;180:273-80.
17. Bryant JM, Harris SR, Parkhill J, et al. Whole-genome sequencing to establish relapse or re-infection with Mycobacterium tuberculosis: a retrospective observational study. Lancet Respir Med 2013;1:786-92.
18. East African/British Medical Research Council. Controlled clinical trial of five short-course (4-month) chemotherapy regimens in pulmonary tuberculosis: second report of the 4th study. Am Rev Respir Dis 1981;123:165-70.
19. Singapore Tuberculosis Service/British Medical Research Council. Clinical trial of six-month and four-month regimens of chemotherapy in the treatment of pulmonary tuberculosis: the results up to 30 months. Tubercle 1981;62:95-102.
20. Jindani A. Recent progress in TB clinical trials: results of the RIFAQUIN trial. Presented at the 41st World Conference on Lung Health of the International Union Against Tuberculosis and Lung Disease, Paris, October 30-November 3, 2013. abstract.
21. Merle CS, Fielding KL, Lapujade O, et al. 4-Month regimen for treating drugsusceptible pulmonary tuberculosis: main efficacy and safety results of the OFLOTUB Trial. Presented at the 41st World Conference on Lung Health of the International Union Against Tuberculosis and Lung Disease, Paris, October 30-November 3, 2013. abstract.
22. Park-Wyllie LY, Juurlink DN, Kopp A, et al. Outpatient gatifloxacin therapy and dysglycemia in older adults. N Engl J Med 2006;354:1352-61.
23. Khaliq Y, Zhanel GG. Fluoroquinolone- associated tendinopathy: a critical review of the literature. Clin Infect Dis 2003;36:1404-10.
24. Update: fatal and severe liver injuries associated with rifampin and pyrazinamide for latent tuberculosis infection, and revisions in American Thoracic Society/CDC recommendations - United States, 2001. MMWR Morb Mortal Wkly Rep 2001;50:733-5.
25. Diacon AH, Dawson R, von Groote- Bidlingmaier F, et al. 14-Day bactericidal activity of PA-824, bedaquiline, pyrazinamide, and moxifloxacin combinations: a randomised trial. Lancet 2012;380:986-93.
26. Aber VR, Nunn AJ. Short term chemotherapy of tuberculosis: factors affecting relapse following short term chemotherapy. Bull Int Union Tuberc 1978;53:276-80. (In French.)
27. Phillips PPJ, Fielding K, Nunn AJ. An evaluation of culture results during treatment for tuberculosis as surrogate endpoints for treatment failure and relapse. PLoS One 2013;8(5):e63840.
28. Nunn AJ, Jindani A, Enarson DA. Results at 30 months of a randomised trial of two 8-month regimens for the treatment of tuberculosis. Int J Tuberc Lung Dis 2011;15:741-5.
29. Burman WJ, Goldberg S, Johnson JL, et al. Moxifloxacin versus ethambutol in the first 2 months of treatment for pulmonary tuberculosis. Am J Respir Crit Care Med 2006;174:331-8.
30. Nunn AJ, Phillips PPJ, Mitchison DA. Timing of relapse in short-course chemotherapy trials for tuberculosis. Int J Tuberc Lung Dis 2010;14:241-2.